Children and teenagers with severe, sometimes life-threatening peanut allergies can reduce their risk from accidental exposure with a new treatment approved Friday by the Food and Drug Administration.

But administering the new treatment, called Palforzia and made by Aimmune Therapeutics (AIMT), is cumbersome and carries its own safety risks, which may deter families and allergists from using it.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Adam what do you think of Dbvt’s patch? They have used reactive dose(Eliciting dose) in their trial rather than tolerable dose and seems to be in effort to hide true efficacy.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy